Inhibition of the platelet P2Y12receptor for adenosine diphosphate does not impair the capacity of platelet to synthesize thromboxane A2

Inherited deficiency or pharmacological inhibition of P2Y₁₂R does not affect the platelet capacity to synthesize TxA₂. There is no pharmacological evidence that ACS patients may be safely treated with P2Y₁₂R antagonists without ASA.